

## Curriculum Vitae

### Wesley P. Wheeler

#### Personal data

Year of birth: 1956  
Nationality: American  
Independence: Yes

#### Member of the Supervisory Board of Evotec

First appointment: 2024  
Current term of office: General Annual Meeting 2024 – 2026  
Committees: Remuneration Committee

#### Competences and experiences

- 20+ years as CEO or President
- Corporate restructuring
- Biologic and small molecule manufacturing
- Drug development & regulatory compliance
- Logistics, depot management and biologic storage
- Clinical laboratory and clinical trials management
- Quality Assurance
- Operational turnarounds
- Marketing
- M&A and corporate integration
- Supply chain operations
- Procurement management
- Lean Six Sigma and Operational Excellence
- Engineering & construction management
- 12 years living / operating in foreign countries

#### Current occupation:

2024 – Present: CEO & Board Director, LabConnect Inc.

**Career Highlights:****2019 – 2023****President, UPS Healthcare**

UPS Healthcare Division is a \$10 billion vertical business unit within UPS. The Healthcare Division, comprising 10,000 employees and managing over 17m square feet of GMP space in 35 countries, provides comprehensive logistics solutions - from clinical to commercial – throughout the world.

**2011 – 2019****Chief Executive Officer & Director, Marken, a UPS Company**

Marken is a \$1billion leading specialty clinical supply chain company serving the global pharmaceutical and healthcare industries. Services include central lab specimens logistics, depot storage & distribution, direct to patient services, 4PL management, customs brokerage, kit building and clinical distribution project management. Marken serves 49,000 investigator sites in over 150 countries from 45 worldwide locations. The company was acquired by UPS in December, 2016.

**2007 – 2010****President, Chief Executive Officer & Director, Patheon (now ThermoFisher)**

The pharmaceutical industry's leading contract manufacturing and formulation development company serving the pharmaceutical industry. Publicly traded on the TSX, now privately held and merged with DSM Pharma Products.

**2003 – 2007****President, Valeant Pharmaceuticals International Inc. (now Bausch Health)**

Valeant is a leading specialty pharmaceuticals company. The company manufactures and sells products in several therapeutic categories. During this time, I was responsible for the North American business unit, global marketing, acquisitions and corporate development. Acquired Xcel Pharmaceuticals and several products during this period. I was responsible for the R&D division from 2006-2007, which included the late stage development of retigabine (Potiga).

**2002 – 2003****Chief Executive Officer, DSM (now ThermoFisher)**

DSM is a leading manufacturing company based in the Netherlands. A subsidiary of DSM Pharmaceutical Products, based in Greenville, NC. The Greenville facility employed 1,200 people and was the third largest employer in Pitt County. Many important biological drugs were launched from this site and continue to supply the industry.

**1989 – 2002****Senior Vice President – Manufacturing and Supply, GlaxoSmithKline**

Responsibilities included the management of strategy and logistics for the global manufacturing & supply division, based in London and RTP. During this period, GSK consolidated all manufacturing, procurement and logistics under one central division and put in place a five-year transformational change program which ultimately reduced the cost of goods with few sites and better processes. LeanSixSigma was introduced to GSK twice during this period.

**1978 – 1989****Field Engineer, Cost & Schedule Engineer – ExxonMobil Corp**

**Qualifications:**

1992	California Lutheran University Masters of Business Administration, Finance
1974 - 1978	Worcester Polytechnic Institute BSME, Mechanical Engineering, with distinction

**Current mandates in listed companies:**

n/a

**Current mandates in non-listed companies:**

Envirotainer	Director of the Board
Argenta	Director of the Board

**Other current mandates:**

Cairn Therapeutics	Investor / member of the Board
Belhaven Biopharma	Investor / member of the Board

*Latest update: February 2026*